Clinical Evidence: What the Research Shows for Both Options
Can I Change From Wegovy to Mounjaro: Understanding Your Treatment Options
When evaluating whether you can change from Wegovy to Mounjaro, it's essential to understand that both are prescription-only medicines requiring clinical assessment and prescriber approval. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural satiety hormones, whilst Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors as a dual agonist mechanism. The decision to switch between these medications should always involve consultation with a qualified prescriber who can assess your individual response, tolerance, and treatment goals. Your medical history, current progress, and any side effects experienced will influence whether changing from Wegovy to Mounjaro represents an appropriate therapeutic decision.
Both medications are designed to work alongside a reduced-calorie diet and increased physical activity as part of a comprehensive weight management programme. Clinical evidence supports both treatments, though they operate through different mechanisms and have distinct dosing schedules, storage requirements, and cost structures. EverydayMeds provides access to both options through our GPhC-registered pharmacy (#9012878), ensuring you receive genuine, properly stored medication with appropriate clinical oversight. Our prescribers can evaluate whether switching from Wegovy to Mounjaro aligns with your treatment objectives and medical profile.
Weight Loss Results UK: Clinical Trial Evidence and Real-World Outcomes
The STEP clinical trial programme provides robust evidence for Wegovy's effectiveness in weight management among UK populations. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo, as published by Wilding et al. in the New England Journal of Medicine, 2021. STEP 3 demonstrated even higher results of approximately 16% when combined with intensive behavioural therapy, whilst STEP 5 showed sustained weight loss of 15.2% maintained at two years. The SELECT cardiovascular outcomes trial revealed an additional 20% reduction in major cardiovascular events, highlighting broader health benefits beyond weight management.
For patients considering whether they can change from Wegovy to Mounjaro, understanding these evidence bases helps inform treatment decisions. Mounjaro's clinical trials showed different weight loss profiles, though direct comparisons aren't appropriate due to varying trial designs, populations, and endpoints. Both medications have demonstrated efficacy in clinical settings when used as part of comprehensive lifestyle interventions. The choice between continuing Wegovy or changing to Mounjaro should reflect individual treatment response, tolerability, and practical considerations rather than head-to-head efficacy comparisons.
Wegovy Pricing and Value: Transparent Costs for UK Patients
EverydayMeds offers competitive pricing for Wegovy across all dose strengths, with transparent costs and convenient bundling options. Single pens start at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles provide convenience for dose escalation, including the Intro Duo (0.25mg & 0.5mg) for £169.99 and Progress Duo (0.5mg & 1mg) for £189.99. New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 for additional savings.
For patients questioning whether they can change from Wegovy to Mounjaro, cost considerations often influence treatment decisions alongside clinical factors. Our 3-pen bundles offer extended supply security, such as the Intro Trio covering your first three dose increases for £299.99, or the Ultimate Stability Trio providing three months of maintenance 2.4mg pens for £649.99. All prices reflect final costs after discount codes are applied at checkout, ensuring transparency without hidden fees. Both Wegovy and Mounjaro are available through our platform, allowing prescribers to recommend the most cost-effective option for your individual circumstances.
How Wegovy Works: GLP-1 Mechanism and Appetite Regulation
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of naturally occurring incretin hormones that regulate appetite and food intake. When administered, semaglutide binds to GLP-1 receptors in the brain's appetite control centres, promoting feelings of fullness and reducing food cravings between meals. This mechanism slows gastric emptying, meaning food remains in the stomach longer, contributing to sustained satiety after smaller portion sizes. The medication also influences reward pathways associated with food, potentially reducing the appeal of high-calorie, palatable foods that often undermine weight management efforts. Unlike stimulant-based appetite suppressants, Wegovy works through natural hormonal pathways, supporting more sustainable eating pattern changes when combined with dietary counselling and lifestyle modifications.
Ordering Process: From Assessment to Delivery
Beginning your Wegovy journey through EverydayMeds involves a streamlined three-step process designed for convenience whilst maintaining clinical safety standards. The online clinical assessment takes approximately three minutes to complete, covering medical history, current medications, weight management goals, and any contraindications that might affect treatment suitability. Following submission, our qualified prescribers review your assessment within three working days (or 24 hours with express service), ensuring appropriate clinical oversight before dispensing any prescription-only medicine. Once approved, your Wegovy pens are dispatched via next-day delivery using temperature-controlled, cold-chain logistics to maintain medication integrity throughout transit. Our pharmacy team provides ongoing support throughout your treatment journey, including guidance on dose escalation, injection technique, and managing any questions that arise during therapy.
Storage and Practical Considerations When Switching Treatments
Wegovy offers practical storage advantages that may influence decisions about whether to change from Wegovy to Mounjaro, particularly for patients with active lifestyles or frequent travel commitments. Whilst both medications require refrigeration at 2-8°C before first use, Wegovy maintains stability for up to six weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen delivery system provides consistent, accurate dosing with a simple injection process suitable for patients new to injectable medications. Dose escalation follows a structured schedule over 16 weeks, starting at 0.25mg and increasing monthly until reaching the 2.4mg maintenance dose, allowing gradual tolerance development and side effect minimisation. Each pen contains four weekly doses, reducing the frequency of prescription refills compared to daily oral medications, though planning ahead for continuous supply remains important for optimal treatment outcomes.
Switching Considerations: Clinical Factors Beyond Weight Loss Results
The decision to change from Wegovy to Mounjaro extends beyond simple weight loss comparisons to encompass individual tolerance, lifestyle factors, and treatment preferences. Some patients may experience different side effect profiles between GLP-1 monotherapy (Wegovy) and dual GIP/GLP-1 agonism (Mounjaro), potentially influencing long-term adherence and treatment satisfaction. Injection frequency, dose escalation schedules, and storage requirements differ between medications, making practical considerations as important as clinical efficacy in treatment selection. Your prescriber will evaluate your current progress, any adverse effects, and treatment goals when determining whether switching represents an appropriate therapeutic strategy.
Cost considerations also influence treatment continuity, as insurance coverage, private pay affordability, and long-term budget planning affect medication accessibility. EverydayMeds maintains competitive pricing for both options, though the specific dose strengths and escalation schedules may create different monthly costs depending on your treatment stage. Both medications require ongoing commitment to dietary changes and physical activity, meaning the choice between Wegovy and Mounjaro should align with sustainable lifestyle modifications rather than seeking short-term weight loss acceleration.
Expert Guidance: Making Informed Treatment Decisions
Both Wegovy and Mounjaro are available from EverydayMeds, with our clinical team providing expert guidance to help determine which option best suits your individual needs and circumstances. Our GPhC-registered pharmacy (#9012878) ensures access to genuine medications with proper storage, handling, and clinical oversight throughout your treatment journey. The 3-minute online assessment process evaluates medical history, treatment goals, and lifestyle factors that influence medication selection and dosing strategies. Whether continuing with Wegovy or considering a change to Mounjaro, our prescribers provide personalised recommendations based on clinical evidence, individual response patterns, and practical considerations that affect long-term treatment success. Start your assessment today using discount code FIRST40 for new customers, and discover which prescription weight management option offers the best fit for your health objectives at https://everydaymeds.co.uk/collections/wegovy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
